Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.

about

Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38792217

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Second cancer risk assessments ...... mediastinal Hodgkin lymphoma.

@en

type

Item

label

Second cancer risk assessments ...... mediastinal Hodgkin lymphoma.

@en

prefLabel

Second cancer risk assessments ...... mediastinal Hodgkin lymphoma.

@en

P1476

Second cancer risk assessments ...... mediastinal Hodgkin lymphoma.

@en

P2093

Efrossyni Lyraraki

http://www.w3.org/2001/XMLSchema#string

John Damilakis

http://www.w3.org/2001/XMLSchema#string

Michalis Mazonakis

http://www.w3.org/2001/XMLSchema#string

P2860

Solid cancer incidence in atomic bomb survivors: 1958-1998

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

The involved field is back: issues in delineating the radiation field in Hodgkin's disease.

Dose-response relationship for breast cancer induction at radiotherapy dose

Accuracy of out-of-field dose calculations by a commercial treatment planning system.

Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.

Intensity-modulated radiation therapy, protons, and the risk of second cancers.

Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study.

ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context.

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

P304

3866-3874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MP.12327

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28493609

http://www.w3.org/2001/XMLSchema#string